Benzinga''s Top Ratings Upgrades, Downgrades For July 11, 2022
Upgrades For Visteon Corp (NASDAQ: VC ), Exane BNP Paribas upgraded the previous rating of Neutral to Outperform. For the first quarter, Visteon had an EPS of $1.09, compared to year-ago quarter EPS of $0.56. The stock has a 52-week-high of $134.57 and a 52-week-low of $88.82. At the end of the last trading period, Visteon closed at $108.51. For Lear Corp (NYSE: LEA ), Exane BNP Paribas upgraded the previous rating of Underperform to Neutral. In the first quarter, Lear showed an EPS of $1.80, compared to $3.73 from the year-ago quarter. At the moment, the stock has a 52-week-high of $195.43 and a 52-week-low of $118.38. Lear closed at $128.20 at the end of the last trading period. According to BMO Capital, the prior rating for Fate Therapeutics Inc (NASDAQ: FATE ) was changed from Market Perform to Outperform. For the first quarter, Fate Therapeutics had an EPS of $0.68, compared to year-ago quarter EPS of $0.48. The stock has a 52-week-high of $97.43 and a 52-week-low of $17.10. At the end of the last trading period, Fate Therapeutics closed at $30.01.
Benzinga''s Top Ratings Upgrades, Downgrades For July 11, 2022
Upgrades For Visteon Corp (NASDAQ: VC ), Exane BNP Paribas upgraded the previous rating of Neutral to Outperform. For the first quarter, Visteon had an EPS of $1.09, compared to year-ago quarter EPS of $0.56. The stock has a 52-week-high of $134.57 and a 52-week-low of $88.82. At the end of the last trading period, Visteon closed at $108.51. For Lear Corp (NYSE: LEA ), Exane BNP Paribas upgraded the previous rating of Underperform to Neutral. In the first quarter, Lear showed an EPS of $1.80, compared to $3.73 from the year-ago quarter. At the moment, the stock has a 52-week-high of $195.43 and a 52-week-low of $118.38. Lear closed at $128.20 at the end of the last trading period. According to BMO Capital, the prior rating for Fate Therapeutics Inc (NASDAQ: FATE ) was changed from Market Perform to Outperform. For the first quarter, Fate Therapeutics had an EPS of $0.68, compared to year-ago quarter EPS of $0.48. The stock has a 52-week-high of $97.43 and a 52-week-low of $17.10. At the end of the last trading period, Fate Therapeutics closed at $30.01.